Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy

Molecular Therapy

Volumn 8, Issue 3, 2003, Pages 412-424

  Halldén, Gunnel ^a   Hill, Richard ^a   Wang, Yaohe ^a   Anand, Arthi ^a   Liu, Ta Chiang ^a   Lemoine, Nick R ^a   Francis, Jennelle ^a   Hawkins, Lynda ^a   Kirn, David ^a,b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adenovirus; Cancer; Experimental therapeutics; Immunology; Oncolytic; Virology

Indexed keywords

COAT PROTEIN; ONCOLYTIC VIRUS;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; MOUSE; NONHUMAN; TUMOR XENOGRAFT; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0141632785     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00199-0     Document Type: Article

References (52)

1. Kirn, D. (2000). Replication-selective micro-organisms: fighting cancer with targeted germ warfare. J. Clin. Invest. 105: 836-838.
2. Bischoff, J. R., et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376.
3. Heise, C., Sampson, J. A., Williams, A., McCormick, F., Von, H. D., and Kirn, D. H. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3: 639-645.
4. Yu, D., Sakamoto, G., and Henderson, D. R. (1999). Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59: 1498-1504.
5. Yu, D., Chen, Y., Seng, M., Dilley, J., and Henderson, D. R. (1999). The addition of adenovirus region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59: 4200-4203.
6. Heise, C., et al. (2000). An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy. Nat. Med. 6: 1134-1139.
7. Freytag, S. O., Rogulski, K. R., Paielli, D. L., Gilbert, J. D., and Kim, J. H. (1998). A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9: 1323-1333.
8. Fueyo, J., et al. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19: 2-12.
9. Kurihara, T., Brough, D. E., Kovesdi, I., and Kufe, D. W. (2000). Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 106: 763-771.
10. Johnson, L., et al. (2002). Cytosine deaminase-armed selectively-replicating adenovirus for the treatment of cancer. Proc. Am. Assoc. Cancer Res., Abstract 3257.
11. Ramachandra, M., et al. (2001). Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat. Biotechnol. 19: 1035-1041.
12. Hallenbeck, P., Jacubczak, J., Ryan, P., Hawkins, L., Ling, X., and Forry-Schaudies, S. (2002). Oncolytic adenoviruses dependent on two prevalent alterations in human cancer: Disregulation of the Rb-pathway and telomerase. Mol. Ther. 5: 165 [Abstract].
13. Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A., and Wold, W. (2000). Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74: 6147-6155.
14. Kirn, D. (2000). Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene: 6660-6668.
15. Kirn, D., Martuza, R. L., and Zwiebel, J. (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 7: 781-787.
16. Wold, W. S., Hermiston, T. W., and Tollefson, A. E. (1994). Adenovirus proteins that subvert host defenses. Trends Microbiol. 2: 437-443.
17. Sparer, T. E., Tripp, R. A., Dillehay, D. L., Hermiston, T. W., Wold, W. S., and Gooding, L. R. (1996). The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. J. Virol. 70: 2431-2439.
18. Coffey, M., Strong, J., Forsyth, P., and Lee, P. (1998). Reovirus therapy of tumors with activated ras pathway. Science 282: 1332-1334.
19. Rommelaere, J., and Cornelis, J. J. (1991). Antineoplastic activity of parvoviruses. J. Virol. Methods 33: 233-251.
20. Lichtenstein, D. L., Krajcsi, P., Esteban, D. J., Tollefson, A. E., and Wold, W. S. (2002). Adenovirus RIDbeta subunit contains a tyrosine residue that is critical for RID-mediated receptor internalization and inhibition of Fas- and TRAIL-induced apoptosis. J. Virol. 76: 11329-11342.
21. Wold, W. S., Tollefson, A. E., and Hermiston, T. W. (1995). E3 transcription unit of adenovirus. Curr. Top. Microbiol. Immunol. 199: 237-274.
22. Dimitrov, T., Krajcsi, P., Hermiston, T. W., Tollefson, A. E., Hannink, M., and Wold, W. S. (1997). Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes. J. Virol. 71: 2830-2837.
23. Hermiston, T. W., Tripp, R. A., Sparer, T., Gooding, L. R., and Wold, W. S. (1993). Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. J. Virol. 67: 5289-5298.
24. Shisler, J., Duerksen, H. P., Hermiston, T. M., Wold, W. S., and Gooding, L. R. (1996). Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. J. Virol. 70: 68-77.
25. Kirn, D. (2001). Clinical research results with d/1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 8: 89-98.
26. Nemunaitis, J., et al. (2000). Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60: 6359-6366.
27. DeWeese, T., et al. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61: 7464-7472.
28. Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., and Henderson, D. R. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57: 2559-2563.
29. Heise, C., Williams, A., Xue, S., Propst, M., and Kirn, D. (1999). Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59: 2623-2628.
30. Heise, C., Williams, A., Olesch, J., and Kirn, D. (1999). Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. 6: 499-504.
31. Ginsberg, H. S., et al. (1991). A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. USA 88: 1651-1655.
32. Eggerding, F. A., and Pierce, W. C. (1986). Molecular biology of adenovirus type 2 semipermissive infections: I. Viral growth and expression of viral replicative functions during restricted adenovirus infection. Virology 148: 97-113.
33. Silverstein, G., and Strohl, W. A. (1986). Restricted replication of adenovirus type 2 in mouse Balb/3T3 cells. Arch. Virol. 87: 241-264.
34. Duncan, S., et al. (1978). Infection of mouse liver by human adenovirus type 5. J. Gen. Virol. 40: 45-61.
35. Tomko, R., Xu, R., and Philipson, L. (1997). HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA 94: 3352-3356.
36. Ganly, I., Mauntner, V., and Balmain, A. (2000). Productive replication of human adenoviruses in mouse epidermal cells. J. Virol. 74: 2895-2899.
37. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3: 639-645.
38. Ginsberg, H. S., et al. (1989). Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc. Natl. Acad. Sci. 86: 3823-3827.
39. Ginsberg, H. S., et al. (1991). A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. USA 88: 1651-1655.
40. Duncan, S., Gordon, F., Gregory, D., McPhie, J., Postlethwaite, R., and Willcox, H. (1978). Infection of mouse liver by human adenovirus type 5. J. Gen. Virol. 40: 45-61.
41. Tollefson, A. E., Ryerse, J. S., Scaria, A., Hermiston, T. W., and Wold, W. S. (1996). The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with ADP mutants. Virology 220: 152-162.
42. Gooding, L. R. (1994). Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect Agents Dis. 3: 106-115.
43. Toda, M., Rabkin, S., Kojima, H., and Martuza, R. (1999). Herpes simplex virus as an in situ cancer vaccine for the induction of specific antitumor immunity. Hum. Gene Ther. 10: 385-393.
44. Martuza, R. (2000). Conditionally replicating herpes viruses for cancer therapy. J. Clin. Invest. 105: 841-846.
45. Wu, J. T., Byrne, H. M., Kirn, D. H., and Wein, L. M. (2001). Modeling and analysis of a virus that replicates selectively in tumor cells. Bull. Math. Biol. 63: 731-768.
46. Krajcsi, P., et al. (1996). The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. J. Virol. 70: 4904-4913.
47. Wold, W. S., Hermiston, T. W., and Tollefson, A. E. (1994). Adenovirus proteins that subvert host defenses. Trends Microbiol. 2: 437-443.
48. Hermiston, T. W., Tripp, R. A., Sparer, T., Gooding, L. R., and Wold, W. S. (1993). Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. J. Virol. 67: 5289-5298.
49. Hermiston T., Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J. Clin. Invest. 105: 1169-1172.
50. Khuri, F., et al. (2000). A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer. Nat. Med. 6: 879-885.
51. Branton, P. E., and Roopchand, D. E. (2001). The role of adenovirus E4orf4 protein in viral replication and cell killing. Oncogene 20: 7855-7865.
52. Nagtegall, et al. (2001). Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study. BMC Cancer 1: 7.